$17.50
▼ $-0.23
(-1.30%)
Vol 301K
3
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$474.4M
ROE
-25.1%
D/E
1.49
Beta
1.59
52W
$3–$14
Wall Street Consensus
13 analysts · Apr 20265
Strong Buy
5
Buy
3
Hold
0
Sell
0
Strong Sell
76.9%
Buy Rating
Price Chart
Similar Stocks
XERS
Xeris Biopharma Holdings Inc
$1.3B
AMPH
Amphastar Pharmaceuticals Inc
P/E 11.0
$1.2B
PCRX
Pacira Biosciences Inc
P/E 51.9
$1.1B
PHAT
Phathom Pharmaceuticals Inc
$1.2B
OMER
Omeros Corp
$1.2B
SGP
SpyGlass Pharma Inc
RLMD
Relmada Therapeutics Inc
$354.2M
ARVN
Arvinas Inc
$761.7M
ETON
Eton Pharmaceuticals Inc
$453.5M
About BioAge Labs, Inc. - Common Stock
BIOA - це фармацевтична компанія, що спеціалізується на розробці та виробництві інноваційних лікарських засобів для лікування складних захворювань. Компанія займає нішеву позицію на ринку, зосереджуючись на розробці препаратів з використанням передових біотехнологій. Її ключова конкурентна перевага - це сильний науково-дослідний потенціал та портфель перспективних продуктів на різних стадіях клінічних випробувань.
Earnings
Beat rate: 80.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.75 | $-0.72 | +$0.03 |
| Sep 2025 | $-0.60 | $-0.56 | +$0.04 |
| Jun 2025 | $-0.49 | $-0.60 | $-0.11 |
| Mar 2025 | $-0.54 | $-0.36 | +$0.18 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | $1.5M | $2.4M | $2.1M |
| Net Income | -$23.4M | -$21.1M | -$12.9M | -$21.6M | -$20.2M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -25.4% | -25.4% | -25.4% | -25.4% | -25.4% | -25.1% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -894.0% | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 1.90 | 1.90 | 1.90 | 1.90 | 1.90 | 1.49 |
| Current Ratio | 13.21 | 13.21 | 13.21 | 13.21 | 13.21 | 11.87 |
Key Ratios
ROA (TTM)
-22.8%
P/B
0.6
EPS (TTM)
$-2.04
52W High
$14.46
52W Low
$2.88
$2.88
52-Week Range
$14.46
Financial Health
Free Cash Flow
-$16.1M
Net Debt
-$208.4M
Cash
$215.6M
Total Debt
$7.1M
As of Sep 30, 2025
How does BIOA compare to Pharmaceuticals peers?
Peer group: Micro-cap Pharmaceuticals (All) · 171 companies
BIOA valuation vs Pharmaceuticals peers
P/E ratio
—
▼
0%
below
peers
(22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(5.0)
vs Peers
vs Industry
Overvalued
P/B ratio
0.6
▼
70%
below
peers
(2.1)
vs Peers
vs Industry
Undervalued
Div yield
—
▼
0%
below
peers
(2.0%)
vs Peers
vs Industry
Low yield
BIOA profitability vs Pharmaceuticals peers
ROE
-25.1%
▲
54%
above
peers
(-54.3%)
vs Peers
vs Industry
Below avg
Net margin
—
▼
0%
below
peers
(-47.4%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(68.3%)
vs Peers
vs Industry
In line
ROA
-22.8%
▲
39%
above
peers
(-37.4%)
vs Peers
vs Industry
Below avg
BIOA financial health vs Pharmaceuticals peers
D/E ratio
1.5
▼
3%
below
peers
(1.5)
vs Peers
vs Industry
In line
Current ratio
11.9
▲
253%
above
peers
(3.4)
vs Peers
vs Industry
Strong liquidity
Beta
1.6
▲
70%
above
peers
(0.9)
vs Peers
vs Industry
More volatile
BIOA fundamentals radar
BIOA
Peer median
Industry
BIOA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
BIOA vs peers: key metrics
Latest News
No related news yet